The ADAPT Her2+/HR- Study is a WSG sponsored study, which involves the dynamic testing of Her2+/HR- breast cancer patients. Palleos delivers a full-service management including Data Management, Project Management, Regulatory Affairs, Monitoring, IT infrastructure, site management, and financial management in Germany. For scientific details see the Sponsor’s homepage.
- 220 Patients, 35 Sites [LPI: Q1 2016]
- Indication: Oncology
- Sponsor: Westdeutsche Studiengruppe
- Acting as preferred provider for the WSG